BACKGROUND: Rare reports on patients with congenital myopathy with excess of muscle spindles (CMEMS), hypertrophic cardiomyopathy and variable features resembling Noonan syndrome have been published, but the genetic basis of this condition is so far unknown. METHODS AND RESULTS: We analysed PTPN11 and RAS genes in five unrelated patients with this phenotype, and found HRAS mutations in four of them. Two disease-associated mutations, G12V and G12S, have previously been observed in patients with Costello syndrome (CS), and two other mutations, E63K and Q22K, are novel. All four mutations are predicted to enhance downstream HRas signalling, suggesting that CMEMS is a developmental consequence of sustained HRas activation in skeletal muscle. CONCLUSION: This type of myopathy may represent a previously unrecognized manifestation of CS. However, some patients carrying HRAS mutations may exhibit prominent congenital muscular dysfunction, although features of CS may be less obvious, suggesting that germline HRAS mutations may underlie some cases of otherwise unclassified neonatal neuromuscular disorders.
BACKGROUND: Rare reports on patients with congenital myopathy with excess of muscle spindles (CMEMS), hypertrophic cardiomyopathy and variable features resembling Noonan syndrome have been published, but the genetic basis of this condition is so far unknown. METHODS AND RESULTS: We analysed PTPN11 and RAS genes in five unrelated patients with this phenotype, and found HRAS mutations in four of them. Two disease-associated mutations, G12V and G12S, have previously been observed in patients with Costello syndrome (CS), and two other mutations, E63K and Q22K, are novel. All four mutations are predicted to enhance downstream HRas signalling, suggesting that CMEMS is a developmental consequence of sustained HRas activation in skeletal muscle. CONCLUSION: This type of myopathy may represent a previously unrecognized manifestation of CS. However, some patients carrying HRAS mutations may exhibit prominent congenital muscular dysfunction, although features of CS may be less obvious, suggesting that germline HRAS mutations may underlie some cases of otherwise unclassified neonatal neuromuscular disorders.
Authors: Junji Yamauchi; Yuki Miyamoto; Akito Tanoue; Eric M Shooter; Jonah R Chan Journal: Proc Natl Acad Sci U S A Date: 2005-10-03 Impact factor: 11.205
Authors: L A Quilliam; M M Hisaka; S Zhong; A Lowry; R D Mosteller; J Han; J K Drugan; D Broek; S L Campbell; C J Der Journal: J Biol Chem Date: 1996-05-10 Impact factor: 5.157
Authors: W P de Boode; B A Semmekrot; H J ter Laak; C J van der Burgt; J M Draaisma; E J Lommen; R C Sengers; J M van Wijk-Hoek Journal: Acta Neuropathol Date: 1996-12 Impact factor: 17.088
Authors: Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen Journal: Am J Med Genet A Date: 2019-06-20 Impact factor: 2.802
Authors: Karen W Gripp; Eugenia Bifeld; Deborah L Stabley; Elizabeth Hopkins; Stefanie Meien; Kathy Vinette; Katia Sol-Church; Georg Rosenberger Journal: Am J Med Genet A Date: 2012-07-20 Impact factor: 2.802
Authors: Eleni Giannoulatou; Gilean McVean; Indira B Taylor; Simon J McGowan; Geoffrey J Maher; Zamin Iqbal; Susanne P Pfeifer; Isaac Turner; Emma M M Burkitt Wright; Jennifer Shorto; Aysha Itani; Karen Turner; Lorna Gregory; David Buck; Ewa Rajpert-De Meyts; Leendert H J Looijenga; Bronwyn Kerr; Andrew O M Wilkie; Anne Goriely Journal: Proc Natl Acad Sci U S A Date: 2013-11-20 Impact factor: 11.205
Authors: Tjitske Kleefstra; Saskia B Wortmann; Richard J T Rodenburg; Ernie M H F Bongers; Kinga Hadzsiev; Cees Noordam; Lambert P van den Heuvel; Willy M Nillesen; Katalin Hollody; Gabrielle Gillessen-Kaesbach; Martin Lammens; Jan A M Smeitink; Ineke van der Burgt; Eva Morava Journal: Eur J Hum Genet Date: 2010-11-10 Impact factor: 4.246